Nifty Pharma

How to trade Nifty Pharma, Energy indices today, Dec 11? Check levels here

Stock market today: What are the key support, resistance levels for the Nifty Pharma, and Energy indices? What should be the trading strategy? Here is your trading guide for stock market today

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Ravi Nathani says Nifty FMCG still correcting, Pharma showing bearish trend

The Nifty FMCG index is currently exhibiting a downward trend in the near term, while Nifty Pharma index continues to exhibit a bearish trend in the near term

Ravi Nathani suggests buying dips in Nifty Metal; sell on rise in pharma

Nifty Metal is currently approaching critical support levels between 8,800 and 8,700, while Nifty Pharma Index shows a clear downtrend on the charts

Here's how to trade Nifty Pharma, FMCG and Energy indices on Nov 8; details

The Nifty Energy Index is currently trading within a well-defined range between 39,700 and 38,150

Trump Trade: Strategies for Indian IT, Pharma indices post US elections

Analysts believe that Indian export-oriented sectors such as pharma and IT may experience challenges under Donald Trump's rule. Here's how Nifty IT and Pharma indices are placed on charts.

Nifty IT, Auto, Pharma show weakness on charts: Here's what analysts say

The Nifty IT, Auto, and Pharma indices are all exhibiting short-term downtrends, and the technical indicators suggest limited upside potential

Nifty Pharma rangebound, eyes breakout; check support, target, and more

The Nifty Pharma Index is currently trading within a well-defined range between 23,800 and 22,700. A breakout above or below these levels will likely trigger a directional move

Shilpa Medicare shares rise 3% on receiving CEP for Desmopressin; details

Shilpa Medicare share price surged after the company said that its arm, Shilpa Pharma Lifesciences, has received certificate of suitability (CEP) from EDQM for API, Desmopressin

Nifty Pharma presents sell-on-rise opportunity; your trading strategy here

The Nifty Pharma Index remains range-bound, trading between 23,450 and 22,925. A close above or below these levels would act as a directional trigger, leading to either a bullish or bearish breakout.

Nifty Pharma, FMCG indices range-bound; Check support and other levels here

The Nifty Pharma Index is currently trading in a defined range between 23,700 and 22,700. This suggests that the market is experiencing indecision, with neither buyers nor sellers dominating.

Panacea Biotec gets $20 mn loan from US DFC for capex; stock rises 5%

The shares of Panacea Biotec rose after the company announced that it has secured $20 million in loan from US International Development Finance Corp (DFC).

Nifty FMCG shows signs of near term correction; check key levels here

Support levels are crucial in this corrective phase, and for the Nifty FMCG Index, key support levels are identified at 61,180 and 59,500.

Profit booking on cards for Nifty Pharma, FMCG; check trading strategy

The Nifty Pharma Index is currently showing a bullish trend on the near-term charts but is approaching a significant resistance level around 20,850

Sun Pharma inks MoU with Takeda to introduce gastrointestinal drug in India

Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India. The company has entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan tablets in strengths of 10 and 20 mg in India, the Mumbai-based drug major said in a statement. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. "Sun Pharma is a leader in gastroenterology and we are excited to introduce Vonoprazan in India under non-exclusive patent license from Takeda," Sun Pharma CEO - India Business Kirti Ganorkar said. The partnership demonstrates the company's commitment to gastrointestinal health by providing patients and healthcare practitioners with a novel treatment option to manage reflux esophagitis and other acid peptic disorders, he added. Gastroesophageal Reflux Disease (GERD) is

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Among individual players, Aurobindo Pharma, Dr Reddys Labs, and Zydus Lifesciences sourced 48 per cent, 47 per cent, and 46 per cent of their total revenues from the US generics segment, respectively

Why did investors dump Marksans Pharma shares post Q4 results? Know here

Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23

Stock trading guide for today: How to approach pharma, FMCG counters?

Technical indicators such as the RSI, MACD, and Stochastic are showing signs of potential correction and underperformance for the Nifty Pharma index

Nifty Energy on decline, Nifty Pharma range bound: Know what charts suggest

The Nifty Energy Index, currently priced at 38,458.00, is displaying a downward trend in the near term according to the charts

Guide to trade in Nifty Pharma, FMCG indices; check what charts suggest

According to Ravi Nathani, an independent technical analyst, the Nifty Pharma index is quoting close to its ley support at 18,325; hence one may consider a buy on dip strategy here.